AMAG Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:AMAG)

Brown Brothers Harriman & Co acquired 38,248 shares as Csx Corp (CSX)'s stock declined 0.55%. 13,186 were reported by Hanseatic Mgmt Services Inc. The stock increased 2.00% or $1.1 during the last trading session, reaching $56.11. The funds in our database now own: 930,630 shares, up from 911,964 shares in 2017Q3.

Analysts expect AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Tuesday, February 27th. Proshare Advsr Ltd Liability Company holds 0% of its portfolio in AMAG Pharmaceuticals, Inc.

The stock decreased 0.48% or $0.3 during the last trading session, reaching $61.67. About 992,098 shares traded. AMAG Pharmaceuticals had a negative net margin of 32.66% and a positive return on equity of 0.96%. The stock underperformed the S&P500 by 27.80%.

Big Money Sentiment decreased to 0.9 in 2017 Q4. It's down -0.10, from 1.02 in 2017Q3. It worsened, as 55 investors sold JPM shares while 802 reduced holdings. 97 funds opened positions while 215 raised stakes. $1.03 million worth of JPMorgan Chase & Co. Waters Parkerson And Lc has 5,600 shares. The tech-heavy Nasdaq Composite Index COMP, -0.36% finished 0.4% lower.

Spark Inv Mgmt Limited Liability Company reported 0.08% stake. Par Inc has 0.38% invested in CSX Corporation (NASDAQ:CSX) for 615,000 shares. Cornerstone Advsrs Inc invested 0.33% in CSX Corporation (NASDAQ:CSX).

Sabby Management Llc, which manages about $835.79M and $1.08 billion US Long portfolio, decreased its stake in Fibrogen Inc (Call) by 1,109 shares to 275 shares, valued at $1.30 million in 2017Q4, according to the filing. (NYSE:JPM). Evanson Asset Mngmt Ltd accumulated 0.16% or 7,428 shares. Fifth Third Bancorporation reported 203,801 shares or 0.08% of all its holdings. (NASDAQ:AMAG). Parametric Portfolio Assocs Limited Liability Corporation owns 361,806 shares. It also upped Canadian Nat Res Ltd (NYSE:CNQ) stake by 29,700 shares and now owns 215,770 shares. Perrigo Company Plc (NYSE:PRGO) was reduced too. "Buy" rating has 2, "Sell" are 0, while 6 are "Hold". Therefore 55% are positive. On Thursday, January 18 the firm has "Hold" rating by Piper Jaffray given. TD Securities maintained Brookfield Asset Management Inc. The SI to Amag Pharmaceuticals Inc's float is 28.77%. The rating was initiated by Citigroup on Thursday, January 19 with "Buy". On Monday, February 22 the stock rating was upgraded by Bank of America to "Buy".

Wall Street Analysts suggested rating of 2.8. (NASDAQ:AMAG) rating. Jefferies has "Buy" rating and $16.0 target. The rating was downgraded by Raymond James on Monday, January 9 to "Underperform". The firm has "Hold" rating by Piper Jaffray given on Thursday, January 18. Cowen reaffirmed a "hold" rating and set a $25.00 target price on shares of AMAG Pharmaceuticals in a research report on Tuesday, February 27th. About 306,998 shares traded. ValuEngine raised shares of AMAG Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 28th.

A number of brokerages recently issued reports on AMAG. The rating was maintained by Cantor Fitzgerald on Wednesday, February 14 with "Hold". The firm earned "Overweight" rating on Friday, November 3 by Morgan Stanley. The original version of this piece of content can be accessed at (NASDAQ:AMAG) for 25,339 shares. In phrases of Market analysis and buying and selling signals, RSI moving above the horizontal 30 reference standard is regarded as a bullish indicator, at the same time as the RSI transferring under the horizontal 70 reference standard is visible to be a bearish indicator. The company was maintained on Thursday, November 9 by UBS. Pnc Financial Services holds 0% or 13,161 shs in its capital. (NASDAQ:AMAG) on Wednesday, May 4 with "Outperform" rating. On Wednesday, February 14 Cantor Fitzgerald maintained AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. Beta value of the stock is marked at 0.10. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa (prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.